Af­fimed’s ear­ly lung can­cer da­ta dis­ap­point; In­dap­ta's $22M round

Plus, news about Akamis Bio, Tenaya Ther­a­peu­tics, Re­vi­va, Ac­tu­ate Ther­a­peu­tics, CG On­col­o­gy and Can­del Ther­a­peu­tics:

Af­fimed shares ear­ly lung can­cer da­ta: In a Phase 1 …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER